Karyopharm Therapeutics Inc. (NASDAQ:KPTI) a clinical-stage pharmaceutical company, announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with advanced or metastatic solid tumors and an ongoing Phase 1b food effects study of Selinexor in patients with advanced sarcomas at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Karyopharm Therapeutics Inc (NASDAQ:KPTI) weekly performance is -4.11%. On last trading day company shares ended up $25.17. Analysts mean target price for the company is $48.25. Karyopharm Therapeutics Inc (NASDAQ:KPTI) distance from 50-day simple moving average (SMA50) is -12.15%.
On June 5, Titan Machinery Inc. (NASDAQ:TITN) a leading network of full-service agricultural and construction equipment stores, reported financial results for the fiscal first quarter ended April 30, 2014. For the first quarter of fiscal 2015, revenue was $465.5 million, compared to $441.7 million in the first quarter last year. Equipment sales were $345.0 million for the first quarter of fiscal 2015, compared to $334.7 million in the first quarter last year. Parts sales were $68.4 million for the first quarter of fiscal 2015, compared to $62.8 million in the first quarter last year. Revenue generated from service was $37.1 million for the first quarter of fiscal 2015, compared to $32.0 million in the first quarter last year. Titan Machinery Inc. (NASDAQ:TITN) shares fell -5.19% in last trading session and ended the day on $16.98. Gross Margin is 15.60% and its return on assets is 0.70%. Titan Machinery Inc. (NASDAQ:TITN) quarterly performance is 3.98%.
Hyperion Therapeutics, Inc. (NASDAQ:HPTX) announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs), and that the RAVICTI NDS was granted Priority Review. Standard review in Canada takes 18 months or more and Priority Review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review time to approximately six months. Hyperion Therapeutics Inc (NASDAQ:HPTX) shares moved down -9.41% in last trading session and was closed at $26.95, while trading in range of $26.31 – $29.25. Hyperion Therapeutics Inc (NASDAQ:HPTX) year to date (YTD) performance is 33.28%.
First NBC Bank Holding Company (NASDAQ:NBCB) was downgraded by investment analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating in a note issued to investors on Friday,TheFlyOnTheWall.com reports. First NBC Bank Holding Company (NASDAQ:NBCB) ended the last trading day at $32.04. Company weekly volatility is calculated as 4.04% and price to cash ratio as 4.89. First NBC Bank Holding Company (NASDAQ:NBCB) showed a negative weekly performance of -5.49%.
On May 20, Caesars Entertainment Corporation (CZR) and Caesars Acquisition Company (NASDAQ:CACQ) announced the closing of the previously announced sale of Harrah’s New Orleans from Caesars Entertainment Operating Company, Inc. to Caesars Growth Partners after receiving approval from the Louisiana Gaming Control Board on May 19. Caesars Acquisition Company (NASDAQ:CACQ) net profit margin is 33.20% and weekly performance is -5.15%. On last trading day company shares ended up $11.43. Analysts mean target price for the company is $13.50. Caesars Acquisition Company (NASDAQ:CACQ) distance from 50-day simple moving average (SMA50) is -12.35%.
Leave a Reply